Therapeutic vaccination for glioblastoma elicited by retargeted oncolytic herpes virus.

ABSTRACT:

Background

Glioblastoma is an aggressive tumor with poor prognosis and limited treatment options due to its resistance to chemotherapy and radiotherapy, high heterogeneity, and ability to evade the immune system. Nevertheless, immunotherapy and oncolytic virotherapy are emerging as promising strategies. This study aimed to evaluate the therapeutic efficacy of an engineered oncolytic Herpes Simplex Virus for glioblastoma treatment.

Methods

We investigated the efficacy of R-115, a retargeted oncolytic Herpes Simplex Virus directed against the human epidermal growth factor receptor 2 (HER2) and engineered to express murine interleukin-12, in an immunocompetent glioblastoma model that recapitulates HER2 tumor heterogeneity. We tested the translatability and reliability of R-115

SUBMITTER: Piaggio F 

PROVIDER: S-EPMC12815124 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature